Genomed Spólka Akcyjna

Equities

GEN

PLGNOMD00024

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 23:00:00 24/06/2024 BST			5-day change	1st Jan Change
28 ^PLN	-.--%		-.--%	-6.04%

05-13	Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-14	Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2024

May 13, 2024 at 03:23 pm

Genomed Spólka Akcyjna reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was PLN 5.03 million compared to PLN 5.78 million a year ago. Net loss was PLN 0.615093 million compared to PLN 0.144948 million a year ago.

Latest news about Genomed Spólka Akcyjna

Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-14	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-15	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	14/02/23	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2021	14/05/21	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	12/02/21	CI
Diagnostyka Sp. z o.o. completed the acquisition of an unknown stake in Genomed Spólka Akcyjna from MCI.Credit Ventures 2.0 FIZ of MCI Capital TFI SA.	10/06/18	CI
Diagnostyka Sp. z o.o. made an offer to acquire an unknown stake in Genomed Spólka Akcyjna from MCI.Credit Ventures 2.0 FIZ of MCI Capital TFI SA.	27/05/18	CI

Chart Genomed Spólka Akcyjna

Duration

Period

More charts

Company Profile

Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Companyâs offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Companyâs activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOMED SPÓLKA AKCYJNA	-6.04%	9.2M
MODERNA, INC.	+18.33%	45.51B
IQVIA HOLDINGS INC.	-8.77%	38.52B
LONZA GROUP AG	+37.94%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+27.94%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+12.93%	25.92B
UNITED THERAPEUTICS CORPORATION	+47.59%	14.13B
MEDPACE HOLDINGS, INC.	+34.53%	12.73B
BIO-TECHNE CORPORATION	-7.17%	11.29B

Other Biotechnology & Medical Research